{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:05:10Z","timestamp":1768820710585,"version":"3.49.0"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1982,4,1]],"date-time":"1982-04-01T00:00:00Z","timestamp":386467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1982,4]]},"abstract":"<jats:p>The in vitro activity of norfloxacin (MK-0366) compared with that of beta-lactam antibiotics and, where appropriate of gentamicin or metronidazole was assessed against recent clinical isolates of common bacteria. The compound was highly active against most enterobacteria (minimal inhibitory concentrations [MICs], 0.008 to 32 micrograms\/ml; 90% inhibited by 0.25 micrograms\/ml), Haemophilus influenzae (MICs, 0.03 to 0.12 micrograms\/ml), and Neisseria gonorrhoeae (MICs, 0.008 to 0.016 micrograms\/ml). It was also active against Pseudomonas aeruginosa (MICs, 0.12 to 2 micrograms\/ml), most other pseudomonads (MICs, 0.03 to 32 micrograms\/ml), and Acinetobacter calcoaceticus (MICs 0.06 to 4 micrograms\/ml). Norfloxacin was somewhat less active against staphylococci (MICs, 0.25 to 4 micrograms\/ml; 1 microgram\/ml required to inhibit 50% of isolates) and streptococci (MICs, 0.5 to 64 micrograms\/ml). Members of the Bacteroides fragilis group of anaerobes were relatively resistant to norfloxacin (MICs, 8 to 128 micrograms\/ml), as were most other anaerobes.<\/jats:p>","DOI":"10.1128\/aac.21.4.604","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:03:40Z","timestamp":1340841820000},"page":"604-607","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":68,"title":["In vitro antibacterial activity of norfloxacin (MK-0366)"],"prefix":"10.1128","volume":"21","author":[{"given":"A","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.21.4.604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.21.4.604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:17:47Z","timestamp":1645453067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.21.4.604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,4]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1982,4]]}},"alternative-id":["10.1128\/AAC.21.4.604"],"URL":"https:\/\/doi.org\/10.1128\/aac.21.4.604","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,4]]},"assertion":[{"value":"1982-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}